This is such an important point. Showing the day 14 reduction in mortality at 82% and then day 28 at 24% says it all. When the leronlimab dosing stopped after 2, the treatment arm became a placebo arm in a way. It is better than just looking at the PE at day 28 because it shows leronlimab was clearly what was working, because as it wore off mortality increased.

It is crazy that as we dig deeper into this trial, the results get more compelling. Most other trials for other drugs work hard to find compelling data and as you look closer the data gets less compelling.